Curated News
By: NewsRamp Editorial Staff
March 27, 2024

Ondine Biomedical Achieves Milestone with NHS Trusts' Adoption of Steriwave

Reddit Discuss on Substack View History of this news story on GitHub
Source News Release

TLDR

  • Ondine Biomedical Inc sealed its first commercial deal with an NHS trust, gaining an early advantage in the healthcare market.
  • The success is attributed to Steriwave's effectiveness in reducing the need for antibiotics, leading to broader NHS adoption and deployment in healthcare facilities.
  • Ondine Biomedical's Steriwave is making the world a better place by improving healthcare outcomes, reducing antibiotic use, and contributing to antimicrobial resistance efforts.
  • Ondine Biomedical Inc is expanding its international presence in Canada, UK, and Spain, while also exploring potential in the United States through FDA phase three trials.

Impact - Why it Matters

The adoption of Steriwave by NHS trusts signifies a major milestone for Ondine Biomedical, with potential implications for the future of healthcare in the UK and beyond. The company's success in reducing the need for antibiotics and contributing to antimicrobial resistance efforts can have a significant impact on patient outcomes and healthcare economics. This news highlights the importance of innovative medical technologies and their potential to address critical healthcare challenges, making it relevant to a wide range of stakeholders, including healthcare professionals, policymakers, and patients.

Summary

Ondine Biomedical Inc Vice President of Sales & Marketing Matt Ross discusses the company's first commercial deal with an NHS trust, focusing on Pontefract and Pinderfields hospitals. The deal follows a successful 500-patient elective hip and knee surgical quality initiative at Pontefract. The company aims to develop a business case for broader NHS adoption, based on successful outcomes and health economics work. Ondine's commercial momentum is also highlighted, including the deployment of Steriwave in eight new healthcare facilities and expansion in Canada, the UK, and Spain. The success is attributed to Steriwave's effectiveness in reducing the need for antibiotics and its alignment with antimicrobial resistance efforts. Ondine plans to continue expanding in European markets, capitalize on its success in Canada, and explore potential in the United States through FDA phase three trials.

Source Statement

This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Ondine Biomedical Achieves Milestone with NHS Trusts' Adoption of Steriwave

blockchain registration record for the source press release.